moosey and others, tbh, this is why I am a bit confused over the HK presentation which put the Hermia product ahead of the Breast product. I would have thought because of the risks involved, there would be a need for extensive clinical trials and FDA/CE approval before this product got anything like broad acceptance in the medical community (and in fact, given the J&J experience, PNV would be quite silly to get ahead of themselves in this for fear of a massive class action).
The stated aim of having a Hernia product in the market in 2019 doesn't ring true to me. I am hoping for some clarity in the half-yearly. This has certainly been a worthwhile discussion.
blue skies, page-24
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.040(1.57%) |
Mkt cap ! $1.781B | |||
| Open | High | Low | Value | Volume |
| $2.56 | $2.59 | $2.53 | $3.881M | 1.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10150 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 38947 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |